Stromectol and generic ivermectin tablets contain the same active ingredient, ivermectin, and belong to the prescription oral-product category in the United States. The brand name identifies Merck’s originator product and its FDA reference history, while generic names identify approved products from other applicants. That distinction matters when reading a prescription, asking a pharmacist about substitution or comparing a listing that uses Stromectol as a familiar search term. An FDA-approved generic is not a different antiparasitic ingredient merely because the carton, tablet markings or manufacturer name are different.
There are also limits to the simple claim that brand and generic are “the same.” FDA evaluates the relevant generic against a reference listed drug for equivalence, but the individual products can have different labelers, National Drug Codes (NDCs), inactive ingredients and package presentations. A 3 mg tablet and a 6 mg tablet contain different amounts of ivermectin and should not be treated as interchangeable units just because both are oral ivermectin. The precise prescription, product strength, FDA record and pharmacist’s review are more useful than general marketing descriptions of brand or generic quality.
Availability is a separate question from therapeutic equivalence. FDA has identified branded Stromectol 6 mg as no longer marketed in the United States, although an FDA-approved 6 mg generic exists. A discontinuation announcement concerning branded 3 mg tablets further underscores why historical brand information is not proof of current retail supply. Use this comparison to understand what is comparable and what can differ; for the original product’s labeling history, consult the Stromectol brand guide, and for the broader market category see generic ivermectin tablets. A pharmacy must confirm any actual dispensing option.
Stromectol is a trade name associated with Merck’s FDA-approved oral ivermectin tablets. Generic ivermectin refers to oral tablet products approved through abbreviated new drug applications (ANDAs), rather than to a separate active chemical. In an authentic U.S. pharmacy transaction, both are human prescription medicines; neither is equivalent to a veterinary ivermectin product or to the topical ivermectin used in skin care and head-lice products. Comparing the two begins by identifying the same route and the corresponding labeled strength, not by comparing brand recognition alone.
The phrase “generic Stromectol” is common in shopping searches, but it can be imprecise. A pharmacy may list a generic under the ingredient name ivermectin, or an informational catalog may show the Stromectol name to orient readers to the reference brand. Neither wording proves that an original Merck-branded carton is available. The dispensing record should identify the actual product provided, including its name, strength and directions, while the package label and NDC help distinguish the listed product from a historical reference entry.
The decisive comparison has two dimensions. First is FDA product equivalence: whether an approved generic of the corresponding strength has demonstrated the necessary pharmaceutical and bioequivalence criteria. Second is the real-world pharmacy transaction: whether a legally substitutable product can be dispensed under the prescription and state law. A patient looking for the general oral-tablet product family can use the oral ivermectin overview, while this page focuses on the consequences of choosing between a named originator and a generic label.
The practical differences are easier to see when regulatory identity, tablet characteristics and pharmacy access are kept apart. The table compares the originator brand with FDA-approved generics at the product-category level; it does not claim that any particular company or pharmacy has stock available today.
Strength-specific approval and marketing status should always be interpreted separately. The comparison does not combine a branded 3 mg tablet with a generic 6 mg tablet or imply that a discontinued branded strength can be ordered because its FDA reference record remains searchable.
| Comparison factor | Stromectol (originator brand) | Generic oral ivermectin | Meaning for a U.S. pharmacy customer |
|---|---|---|---|
| Active ingredient | Ivermectin | Ivermectin | The ingredient is the same for corresponding oral products; confirm the ordered strength. |
| Product application | Original-brand new drug application (NDA 050742) | Approved abbreviated new drug applications (ANDAs), including 215922 | Different applications document brand and generic regulatory identities. |
| Tablet strengths | Historical branded 3 mg and 6 mg products; 6 mg no longer marketed | FDA-approved 3 mg and 6 mg tablets exist | Approval and discontinued brand status do not establish current stock. |
| Therapeutic equivalence | Serves as the relevant reference listed drug | FDA assesses generics against an appropriate reference and strength | Use the applicable FDA determination or Orange Book rating, not a marketing claim. |
| Appearance and packaging | Brand-specific markings and historical carton/NDC records | May differ by approved applicant and labeler | Different appearance alone does not establish inferior quality or a wrong drug. |
| Inactive ingredients | As listed for the particular branded formulation | Can differ among approved generic formulations | Discuss a known excipient sensitivity with the pharmacist. |
| Prescription access | Requires a valid prescription; availability of branded items must be checked | Requires a valid prescription; pharmacy must verify the actual product | A listing is not proof of supply, a valid prescription or an allowed substitution. |
| Cost interpretation | Brand quote may be unavailable when a product cannot be sourced | Generic price depends on the actual product and payment route | Compare current verified pharmacy quotes for the same prescribed item, not archived prices. |
The FDA generic approval pathway requires evidence that a proposed drug meets applicable standards compared with its reference listed product. For a conventional oral tablet, the agency evaluates pharmaceutical equivalence and bioequivalence within the regulatory requirements. Where products are determined therapeutically equivalent, the expectation is the same clinical effect and safety profile under the conditions in the approved labeling. This conclusion is more meaningful than an unsupported claim that a generic is either automatically weaker or automatically superior.
An especially relevant example is FDA ANDA 215922, approved in January 2025 for ivermectin tablets 3 mg and 6 mg. Its approval letter states that those products were determined bioequivalent and therapeutically equivalent to the corresponding Stromectol reference tablets. The decision concerns the specified applicant and products. It must not be stretched into a claim that every company markets both strengths, or that any package offered online is authentic merely because the active ingredient matches.
The FDA Orange Book records approval identities and therapeutic-equivalence evaluations; they can help a pharmacist assess which labeled products correspond to the prescription. Not every product record shows the same code or marketing status, particularly when historical strengths are involved, so a code should be checked for the exact drug and strength rather than borrowed from a different listing. The separate 3 mg product page and 6 mg product page cover strength-specific identification instead of treating approval as a dose-selection guide.
A major difference between Stromectol and its generics is the history of brand marketing. FDA explicitly notes that Merck’s branded Stromectol 6 mg reference product is no longer marketed in the United States. The agency also determined that its withdrawal from sale was not for reasons of safety or effectiveness, which permits approval of appropriate generic applications relying on that reference. None of this means branded Stromectol 6 mg has returned to sale or that a historical brand listing is a legitimate purchase opportunity.
For Stromectol 3 mg, a 2026 U.S. product-discontinuation notice announced that the branded tablet presentation would be discontinued, with October 31, 2026 identified as the planned date. That notice does not establish the quantity remaining at any particular pharmacy before or after that date. Brand availability should therefore be verified against current official product status and through an actual licensed pharmacy, rather than inferred from a label archive, a search-engine result or a store page that has not been updated.
FDA approval status, marketing status and retail availability describe three different things. An approved product may remain in regulatory databases after its manufacturer has stopped supplying it, and an approved generic may still be unavailable from a particular distributor or pharmacy. A prescriber may need to clarify whether a brand-specific prescription allows a generic fill. For brand-history and availability context use the dedicated Stromectol brand guide; for the cost consequences of an unavailable brand, see Stromectol price factors.
A brand tablet and an FDA-approved generic of the corresponding strength contain the same active ingredient in the same relevant dosage form and route. That does not require their tablets to look identical. Shape, scoring, color, imprint and inactive ingredients may vary among approved products. Differences in the appearance or carton alone are not evidence that one is clinically inferior, but the actual dispensed tablet still must agree with its pharmacy record and product identification.
The National Drug Code (NDC) is particularly useful for identifying a marketed drug listing or package, although an NDC by itself does not prove FDA approval, current supply or the legitimacy of a seller. A drug application number identifies an FDA approval record, and a labeler name identifies the company responsible for a label, which may not be the same entity as the physical manufacturer or distributor. Compare these identifiers with the precise prescription information when a generic carton uses a less familiar company name.
Inactive-ingredient differences may matter when a patient has a known sensitivity to a specific component, but selecting a product should be discussed with a pharmacist or clinician rather than resolved by assuming that a familiar brand is necessarily safer. Packaging changes can also reflect a different generic supplier without a change in the prescribed active drug. A useful verification question is whether the pharmacy can confirm the exact strength, labeler and product identity of the tablets it intends to dispense, rather than whether every visual detail matches a picture found online.
In many U.S. situations a pharmacist may dispense an eligible FDA-approved equivalent generic when a prescription uses an originator brand name. However, substitution is governed by state law, the prescriber’s directions, the exact strength and product involved, and professional dispensing requirements. A prescription specifying a brand, an instruction such as dispense as written, or an unclear strength can change what the pharmacy is permitted to do. There is no blanket guarantee that every brand-named request can be filled with any ivermectin tablet.
An appropriate substitution preserves the drug product and strength required by the prescription and follows the applicable equivalence evaluation. A 6 mg tablet should not be swapped for a 3 mg tablet merely to make an order easier or cheaper; such a change requires professional review of the prescription, not independent tablet arithmetic. Likewise, oral ivermectin tablets are not substitute products for topical ivermectin cream or head-lice lotion. These other formulations have different intended uses and regulatory access requirements.
If a pharmacist explains that the branded presentation is unavailable, ask whether the prescription permits a specific approved equivalent generic and whether the prescriber must be contacted. The ivermectin prescription guide covers the general requirements for a valid prescription; this comparison explains why brand wording and generic identity can affect the actual product dispensed. A refusal or delay may reflect necessary prescription clarification rather than a judgment that the generic is unsuitable.
A specific, product-focused conversation with a licensed pharmacist is more reliable than choosing a brand or generic from an unverified list. The questions below are designed to identify what can actually be dispensed under an existing valid prescription, not to help a patient select an ivermectin dose or obtain the drug without a clinician’s evaluation.
Confirm first what the prescription names; next establish whether the pharmacy’s proposal is an original-brand or generic tablet of the prescribed strength. Then ask about equivalence, the dispensing label, any differences relevant to an identified allergy, and how a change of product would be handled. Pharmacy services and available inventory vary, and a seller’s statement that a brand is “listed” or a generic is “FDA approved” is not by itself a verified dispensing commitment.
| Ask the pharmacist | What the answer should clarify | Why the distinction matters |
|---|---|---|
| Is the product Stromectol or generic ivermectin? | The actual branded or generic drug item intended for the fill | Search names may not match the item dispensed. |
| Which exact tablet strength is on the prescription? | Whether the proposed product matches the authorized 3 mg or 6 mg strength | Strength selection is a prescribing question, not a shopping preference. |
| Is this exact product eligible for substitution? | Applicable equivalence evaluation, prescriber instructions and state rules | Same ingredient does not remove dispensing restrictions. |
| Can you identify the labeler and package NDC? | The specific human-use tablet presentation, if available | Identification is more precise than a generic product photo. |
| Is branded stock actually obtainable? | Whether any genuine brand item can be procured or whether only a generic can be considered | Historical listings do not establish current inventory. |
| Do any excipient differences matter for my record? | Potential relevance of documented allergies or prior adverse reactions | A pharmacist can review product-specific inactive ingredients. |
| What will the dispensing label show? | Actual drug, strength, prescription directions, pharmacy details | The received product needs to match the authorized fill. |
| What happens if the brand cannot be supplied? | Prescriber contact, generic review or other lawful next steps | No pharmacist should promise a brand or an unauthorized substitution. |
Brand-versus-generic price comparisons are meaningful only when both quotes describe real, correctly identified products that can lawfully be dispensed. An old Stromectol price displayed on a comparison website may refer to historical stock, a reference listing or a generic search result. It should not be treated as evidence that a branded carton is presently purchasable. If only a generic is available, the useful comparison is the actual generic prescription fill and its confirmed charges, not a hypothetical brand price.
Even with the same active ingredient, out-of-pocket payment can vary because of the prescribed strength, quantity, pharmacy services, insurance formulary terms and whether a claim is submitted or the customer pays directly. A generic may cost less than a brand in many circumstances, but no particular savings amount is guaranteed. In addition, coverage decisions are based on the patient’s plan and the submitted product, and a quote can change when the prescription or coverage details are finalized.
Price information is most useful when it distinguishes a verified current quote from a historical reference listing. For durable guidance on interpreting the branded reference, consult the Stromectol price guide; for general tablet pricing factors, use the ivermectin price guide or insurance coverage basics. Questions about commercial terms should not obscure the prior clinical decision that an oral ivermectin prescription is appropriate.
The branded-versus-generic distinction does not expand the FDA-approved indications for oral ivermectin. U.S. oral labels identify intestinal strongyloidiasis and onchocerciasis as approved uses. Prescribing for other conditions, including scabies, may occur off-label when a clinician decides it is appropriate; that is separate from whether a pharmacy dispenses an originator product or an approved equivalent generic. The treatment plan and patient-specific precautions must come from a qualified clinician.
Neither the brand nor a generic oral tablet should be confused with topical ivermectin cream used for inflammatory rosacea lesions or lotion used for head lice. Veterinary ivermectin products are also not human-tablet substitutes. The presence of ivermectin in multiple product families is precisely why pharmacy listings should be checked for route, strength and human prescription labeling, even when brand and generic names appear side by side.
For a buyer, the practical result of this comparison is straightforward: determine whether the prescription calls for a particular oral ivermectin product, have a licensed pharmacy verify a legally suitable equivalent if the brand is unavailable, and check the actual medication dispensed. Detailed ordering steps belong to the prescription-pharmacy buying guide, while the local pharmacy guide covers pickup and dispensing conversations. These steps do not guarantee a prescription, stock or a particular clinical outcome.
Stromectol is a trade name for oral ivermectin tablets. FDA-approved generic oral ivermectin tablets contain the same active ingredient. Generic approval also involves product-specific regulatory requirements, but appearance, inactive ingredients, package labeling and the company associated with a product may differ.
FDA determines whether an approved generic meets the requirements for equivalence to its reference product. Products determined therapeutically equivalent are expected to have the same clinical effect and safety profile under the conditions of the labeling. This does not guarantee a particular individual outcome or justify using the medicine for an unapproved condition without clinical review.
FDA identifies the original branded Stromectol 6 mg as no longer marketed in the United States. Its historical approval record does not establish that a branded package is currently available. Approved generic 6 mg tablets are a separate product category; a licensed pharmacy must verify any current fill option.
Stromectol 3 mg has a U.S. brand labeling history, and a 2026 discontinuation notice identified October 31, 2026 as its planned end-of-marketing date. A notice and a regulatory database entry do not reveal the stock held by an individual pharmacy. Its current status should be checked before relying on any brand offer.
Yes. U.S. FDA approval records include generic oral ivermectin tablets in both 3 mg and 6 mg strengths. For example, ANDA 215922 covers both strengths. Approval confirms a regulatory decision about the specified products, not that every manufacturer or pharmacy currently supplies both.
A pharmacy may be able to dispense an appropriate FDA-approved equivalent generic when permitted by the prescription, applicable state law and professional dispensing rules. Brand-only instructions, strength differences or other restrictions may require contact with the prescriber. Patients should not substitute strengths or products independently.
Different approved products can have different tablet markings, colors, shapes, packaging and inactive ingredients. Appearance alone does not establish a problem, but a discrepancy with the pharmacy label or expected product should be resolved with the pharmacist before the medicine is taken.
No. Oral tablets, topical rosacea cream, head-lice lotion and veterinary products are different formulations with different uses and requirements. Even among tablets, the prescribed strength and applicable equivalence determination matter. A pharmacist or clinician must assess whether a proposed replacement is appropriate.
A generic may offer a different cost pathway, but no price relationship is universal. Branded Stromectol may be unavailable for a current quotation, and actual patient charges depend on the prescribed item, quantity, pharmacy and payment arrangements. Compare verified quotes rather than historical online price listings.
Discuss the clinical reason for treatment, the appropriate human-use formulation and any relevant medication or ingredient concerns. If a brand is named on an existing prescription and cannot be supplied, the prescriber and pharmacist can determine whether an FDA-approved equivalent generic may lawfully be dispensed. A brand preference should not determine the dose or indication.